The study
analysed that the PTSD pipeline comprises of 23 drug candidates in
different stages of development. PTSD is a neurological disorder that develops
in people who have experienced a scary or a dangerous event. PTSD can occur in
a person at any age. According to the National Center of PTSD, around seven to
eight out of 100 individuals experience PTSD at some point in their lives. Most
of the people recover from traumatic situation naturally, but those who
continue to experience problems are diagnosed with PTSD. People with PTSD are
used to feel frightened even when they are not in a dangerous situation. PTSD
generally occurs more often in women than men. Various collaboration between
educational institutes, associations, and pharma companies are driving the
therapeutic pipeline of PTSD.
Many
patents have been received during the development of drug candidates for the
treatment of PTSD. In May 2017, Tonix reported the issuance of patent 9 636 408
by the United States Patent and Trademark Office titled “Eutectic Formulations
of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” covering the
composition and manufacture of its proprietary sublingual formulation of very
low dose cyclobenzaprine.
Download
Report Sample at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis/report-sample
Significant
growth in the therapeutic pipeline of PTSD is attributed to increasing
collaboration between educational institutes, associations and pharma
companies. Funds from the non-profit organizations have also been supporting
the pipeline growth of PTSD therapeutics.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ptsd-therapeutics-pipeline-analysis
Some of
the key players developing drugs for the treatment of PTSD include India
Globalization Capital, Inc., Therapade Technologies LLC, Axim Biotechnologies,
Inc. and others.
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886
(USA/Canada)
Email: enquiry@psmarketresearch.com
